The FDA’s decision to expand approval of Sarepta’s (SRPT) Duchenne muscular dystrophy drug on Thursday could mean more “flexible” treatment from the agency for companies like Solid Biosciences (SLDB) and RegenxBio, which are each developing their own Duchenne gene therapies, STATNews’ Adam Feuerstein reports. According to Feuerstein, a biotech fund manager with a fairly large position in Sarepta believes that the FDA’s decision on Elevidsys is a net positive for the field of gene therapy and for patients.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Pfizer DMD gene therapy miss paves way for Sarepta, Solid Biosciences, says Citi
- Sarepta rises as Pfizer âdisappointingâ DMD results remove competitor overhang
- Pfizer failure eliminates DMD competitor for Sarepta, says Baird
- Pfizer’s ‘disappointing’ Phase 3 results positive for Sarepta, says Mizuho
- Pfizer failure removes overhang for Sarepta, says Barclays